Clinical trials: Coagulation Protein Disorders
Congenital Bleeding Disorder, Haemophilia A
A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A
Investigating single dose pharmacokinetics and safety of turoctocog alfa pegol from the pivotal process and turoctocog alfa pegol from the commercial process in patients with severe haemophilia A
- Trial name
- pathfinder™7 (NCT02920398)
- Testing
- turoctocog alfa pegol
- Where
- 14 sites in United States, Denmark and 4 more
- Volunteers
- 21 people
- Sponsor
- Novo Nordisk A/S
Gender Dysphoria, Adult, Blood Coagulation
Comparing the Effects of Sublingual Estradiol Treatment Versus Oral Estradiol With Cyproterone Acetate (CPA) Treatment on The Coagulation System in Transgender Women: A Prospective, Controlled Cohort Study
The goal of this clinical trial is to learn about the effects of different routes of estradiol administration on blood clotting in transgender women starting gender-affirming hormone therapy.
- Conditions
- Gender Dysphoria, Adult, Blood Coagulation, Coagulation Factors, Transgender Persons, M01.777.500
- Trial name
- NCT07145281
- Testing
- Estradiol (E2), Cyproterone Acetate (Androcur, BAY94-8367)
- Where
- Israel
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Tel-Aviv Sourasky Medical Center
Hemophilia, Upper Extremity
Comparison of Upper Extremity Functional Performance in Hemophilic and Healthy Children
The goal of this observational study is to evaluate the functional performance of the upper extremity joints (scapula, shoulder, elbow, and wrist) in haemophilic children and compare muscle strength and ADL limitations with…
- Conditions
- Hemophilia, Upper Extremity, Strength, Performance
- Trial name
- NCT06826209
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Hacettepe University
Hemophilia A
BAY94-9027 PK Study Comparing to Another Long Acting Product
The purpose of this study is to compare the pharmacokinetics of BAY94-9027 and Elocta after intravenous administration.
- Trial name
- NCT03364998
- Testing
- Damoctocog (Jivi, BAY94-9027), Elocta
- Where
- Bulgaria
- Volunteers
- 18 people
- Sponsor
- Bayer
Antithrombin III Deficiency
Belgian Antithrombin Deficiency Registry
Inherited antithrombin deficiency is a rare autosomal dominant disorder that predisposes to the development of venous thromboembolism, even at young age.
- Trial name
- NCT05891899
- Testing
- observation
- Where
- Belgium
- Volunteers
- 1,000 people
- Sponsor
- Universitair Ziekenhuis Brussel
Von Willebrand Disease (vWD)
An Observational Study of Vonicog Alfa (rVWF) in Pediatric Participants With Von Willebrand Disease (vWD)
This study is conducted in Japan of vonicog alfa (rVWF) used to treat pediatric participants with Von Willebrand Disease (vWD). The main aim of the study is to evaluate adverse drug reaction and effectiveness of vonicog alfa…
- Trial name
- NCT07404644
- Testing
- vonicog alfa (rVWF)
- Where
- Japan
- Volunteers
- 13 people
- Sponsor
- Takeda
Hemophilia A, Immune Tolerance
Preventing Inhibitor Recurrence Indefinitely
This study will enroll children who have hemophilia A with inhibitors who successfully completed immune tolerance induction per the ISTH criteria (negative inhibitor titer, recovery >66% of expected, and half-life of >6 hours…
- Trial name
- PRIORITY (NCT04621916)
- Testing
- FVIII, Emicizumab
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Children's Hospital Los Angeles
Chronic Myeloproliferative Disorders, Leukemia
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00005804
- Testing
- cyclophosphamide, allogeneic bone marrow transplantation, radiation therapy
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Hemophilia A
A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A
The goal of this study is to gather more information on safety and efficacy of Kovaltry for the prevention and treatment of bleeds in Chinese children, adolescents/adults with severe hemophilia A.
- Trial name
- NCT04565236
- Testing
- Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 1, Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 2, Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 3
- Where
- 10 sites in China
- Volunteers
- 45 people
- Sponsor
- Bayer
Severe Haemophilia A
Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia A
The rationale of this study is to further fine-tune and individualize prophylactic treatment of patients with severe Haemophilia A with the goal of keeping the trough FVIII level above 1% between doses.
- Trial name
- NCT02256917
- Testing
- Human cl rhFVIII
- Where
- 30 sites in United States, Canada and 7 more
- Volunteers
- 58 people
- Sponsor
- Octapharma
Factor XIII Deficiency, ST-Elevation Myocardial Infarction
Factor XIII and Other Biomarkers in ST Segment Elevation Myocardial Infarction
In medical practice, a combination of clinical exam, electrocardiograms, circulating biomarkers, and imaging is used to gain insights on the prognosis after myocardial infarction.
- Conditions
- Factor XIII Deficiency, ST-Elevation Myocardial Infarction, Myocardial Haemorrhage, Coronary Microvascular Disease
- Trial name
- eXIST (NCT03523624)
- Where
- Italy
- Volunteers
- 35 people
- Sponsor
- University of Padova
Hemophilia A
Impact on French Physician's Haemophilia Treatment Management Decision Based on Systematic Joint Examination
This low interventional study aims to describe if and how the haemophilia treatment management decisions are impacted by a systematic joint examination (ultrasound, functional, physical) in patients with haemophilia A in France.
- Trial name
- A-MOVE (NCT04133883)
- Testing
- Ultrasound, Haemophilia Joint Health Score
- Where
- 20 sites in France
- Volunteers
- 88 people
- Sponsor
- Swedish Orphan Biovitrum
Afibrinogenemia, Hypofibrinogenemia
Fibrinogen Concentrate (Human) - Efficacy and Safety Study
This is a multinational, multicenter, prospective, open-label historically controlled Phase IIIb non-inferiority clinical trial on the efficacy and safety of Fibrinogen Concentrate (Human).
- Conditions
- Afibrinogenemia, Hypofibrinogenemia, Fibrinogen Deficiency
- Trial name
- NCT00916656
- Testing
- Fibrinogen Concentrate, Human (FCH), Cryoprecipitate
- Sponsor
- CSL Behring
Hemophilia A
Safety and Efficacy Extension Study of GreenGene™ F in Previously Treated Patients Diagnosed With Severe Hemophilia A
This study primarily will address the safety and secondarily will assess efficacy of GreenGene™ F in subjects with severe hemophilia A previously treated ≥50 exposure days with a GreenGene™ F, and without presence inhibitor to…
- Trial name
- NCT02027779
- Testing
- GreenGene™ F
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- Green Cross Corporation
Von Willebrand Diseases
Prognostic Value of Implementing VCE on Top in Constitutional VWD-patients With GI-bleeding
Inclusion criteria: Only constitutional VWD-patients fulfilling the inclusion criteria of the French reference center for VWD will be included. Patients with acquired von Willebrand syndrome will not be included.
- Trial name
- NCT04466878
- Volunteers
- 50 people
- Sponsor
- University Hospital, Lille
Coagulation Disorder
Study of Intravenous VMX-C001 in Healthy Subjects and in Combination With Selected Direct Oral Anticoagulants in Healthy Older Subjects
A single centre, double-blind, randomized, parallel group, placebo-controlled study in healthy subjects conducted in two parts: Part 1: Single ascending doses in healthy subjects aged 18 to 49 years to assess safety…
- Trial name
- NCT05152420
- Testing
- VMX-C001, Apixaban, Rivaroxaban
- Where
- Netherlands
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- VarmX B.V.
Hemophilia A or B
PF-06741086 Long-term Treatment in Severe Hemophilia
This study is designed to evaluate the safety, tolerability and efficacy of long-term treatment with PF-06741086 in subjects with severe hemophilia who participated in the 3-month Phase 1b/2 B7841002 study.
- Trial name
- NCT03363321
- Testing
- PF-06741086
- Where
- 8 sites in United States, Brazil and 5 more
- Volunteers
- 20 people
- Sponsor
- Pfizer
Hemophilia
What is the Feasibility of the ISTEP Exercise Test in Boys With Haemophilia
This study will be used to assess the feasibility and sensitivity of using the iSTEP, to assess exercise capacity in boys with haemophilia. The feasibility criteria to be explored includes: 1.
- Trial name
- NCT04076306
- Testing
- iSTEP exercise testing
- Where
- United Kingdom
- Volunteers
- 43 people
- Sponsor
- Great Ormond Street Hospital for Children NHS Foundation Trust
Hemophilia A, Mild, Desmopressin
Genetic Influence of Genetic Factors Influencing the Desmopressin's Efficacy in Mild/Moderate Hemophilia A
Hemophilia A (HA) is an X-linked bleeding disorder caused by mutations in the F8 gene. Bleeding in patients with moderate/mild HA can be treated with either FVIII concentrates or desmopressin (DDAVP).
- Conditions
- Hemophilia A, Mild, Desmopressin, Factor VIII
- Trial name
- GIDEMHA (NCT05628558)
- Testing
- Desmopressin
- Where
- France
- Volunteers
- 800 people
- Sponsor
- Groupe Maladies hémorragiques de Bretagne
Severe Hemophilia A
Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A
This study was divided into four stages: screening period, main trial period, extension period and follow-up period. In the main trial, both groups received FRSW107 prophylactic therapy.
- Trial name
- NCT06136507
- Testing
- FRSW107
- Where
- 13 sites in China
- Volunteers
- 76 people
- Sponsor
- Hangzhou Gensciences Biopharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.